

RENEWAL OF LICENSES ISSUED: (continued)

KINGWOOD	LIEBER-MOORE CARDIOLOGY ASSOCIATES PA DBA TEXAS CARDIOLOGY ASSOCIATES OF HOUSTON	L04622	KINGWOOD	27	01/23/25
LA PORTE	THE CHEMOURS COMPANY FC LLC	L06683	LA PORTE	09	01/31/25
SAN ANTONIO	CHRISTUS SANTA ROSA HEALTH CARE CORPORATION	L02237	SAN ANTONIO	181	01/27/25
WACO	ASCENSION PROVIDENCE	L01638	WACO	79	01/24/25

TRD-202500753  
Cynthia Hernandez  
General Counsel  
Department of State Health Services  
Filed: February 26, 2025

Order Temporarily Placing *N*-Desethyl Isotonitazene  
and *N*-Piperidinyll Etonitazene in Schedule I and  
Placing Ethylphenidate, Butonitazene, Flunitazene, and  
Metodesnitazene in Schedule I



- I. The U.S. Drug Enforcement Administration issued a temporary order placing *N*-ethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine (other name: *N*-desethyl isotonitazene) and 2-(4-ethoxybenzyl)-5-nitro-1-(2-(piperidin-1-yl)ethyl)-1*H*-benzimidazole (other names: *N*-piperidinyl etonitazene; etonitazepipne), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, in schedule I of the Controlled Substances Act effective July 29, 2024. This temporary scheduling order was published in the *Federal Register*, Volume 89, Number 145, pages 60817-60823.

This scheduling action was taken pursuant to *N*-desethyl isotonitazene and *N*-piperidinyl etonitazene having:

1. pharmacological profiles similar to those of the potent benzimidazole-opioids etonitazene and isotonitazene, schedule I opioid substances;
2. high potential for abuse;
3. no currently accepted medical use in treatment in the United States; and
4. a lack of accepted safety for use under medical supervision.

- II. The U.S. Drug Enforcement Administration issued a final rule placing ethylphenidate (other name: ethyl 2-phenyl-2-(piperidin-2-yl)acetate), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act effective November 21, 2024. This final rule was published in the *Federal Register*, Volume 89, Number 204, pages 84281-84286.

This scheduling action was taken pursuant to ethylphenidate having:

1. high potential for abuse that is comparable to other scheduled substances, such as methylphenidate (schedule II);
2. no currently accepted medical use in treatment in the United States; and
3. a lack of accepted safety for use under medical supervision.

- III. The U.S. Drug Enforcement Administration issued a final rule placing butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine), flunitazene (*N,N*-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-

1*H*-benzimidazol-1-yl)ethan-1-amine), and metodesnitazene (*N,N*-diethyl-2-(2-(4-methoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine) including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, in schedule I of the CSA effective October 25, 2024. This final rule was published in the *Federal Register*, Volume 89, Number 207, pages 85047-85050.

This scheduling action was taken pursuant to butonitazene, flunitazene, and metodesnitazene having:

1. a high potential for abuse, similar to etonitazene, fentanyl, and other mu-opioid receptor agonists;
2. no currently accepted medical use in treatment in the United States; and
3. a lack of accepted safety for use under medical supervision.

Pursuant to the Texas Controlled Substances Act, Health and Safety Code Section 481.034(g), at least thirty-one days have expired since notice of the above referenced actions were published in the Federal Register. In the capacity as Commissioner of the Texas Department of State Health Services, Jennifer Shuford, M.D., does hereby order that the substances *N*-desethyl isotonitazene and *N*-piperidinyl etonitazene be temporarily placed in schedule I and ethylphenidate, butonitazene, flunitazene, and metodesnitazene be placed in schedule I.

**NOTE:** Additions are marked by an asterisk (\*).

### **-Schedule I Opiates**

The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation:

- (1) Acetyl- $\alpha$ -methylfentanyl (*N*-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-*N*-phenylacetamide);
- (2) Acetylmethadol;
- (3) Acetyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacetamide);

- (4) Acryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacrylamide) (Other name: acryloylfentanyl);
- (5) AH-7921 (3,4-dichloro-*N*-[1-(dimethylamino)cyclohexymethyl]benzamide);
- (6) Allylprodine;
- (7) Alphacetylmethadol (except levo- $\alpha$ -cetylmethadol, levo- $\alpha$ -acetylmethadol, levomethadyl acetate, or LAAM);
- (8)  $\alpha'$ -Methyl butyryl fentanyl (2-methyl-*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide);
- (9)  $\alpha$ -Methylfentanyl or any other derivative of fentanyl;
- (10)  $\alpha$ -Methylthiofentanyl (*N*-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl] *N*-phenylpropanamide);
- (11) Benzethidine;
- (12)  $\beta$ -Hydroxyfentanyl (*N*-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-*N*-phenylpropanamide);
- (13)  $\beta$ -Hydroxy-3-methylfentanyl (*N*-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-*N*-phenylpropanamide);
- (14)  $\beta$ -hydroxythiofentanyl (Other names: *N*-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-*N*-phenylpropionamide; *N*-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-*N*-phenylpropanamide);
- (15)  $\beta$ -Methyl fentanyl (*N*-phenyl-*N*-(1-(2-phenylpropyl)piperidin-4-yl)propionamide);
- (16)  $\beta'$ -Phenyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*,3-diphenylpropanamide) (Other name: 3-phenylpropanoyl fentanyl);
- (17) Betaprodine;
- (18) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one);
- \* (19) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine);
- (20) Butyryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide);
- (21) Clonitazene;
- (22) Crotonyl fentanyl (Other name: (6-2-5) (E)-*N*-(1-Phenethylpiperidin-4-yl)-*N*-phenylbut-2-enamide);
- (23) Cyclopentyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-Phenylcyclopentanecarboxamide);
- (24) Cyclopropyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylcyclopropanecarboxamide);
- (25) Diampromide;
- (26) Diethylthiambutene;
- (27) Difenoxin;
- (28) Dimenoxadol;
- (29) 2',5'-Dimethoxyfentanyl (*N*-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-*N*-phenylpropionamide);



- (30) Dimethylthiambutene;
- (31) Dioxaphetyl butyrate;
- (32) Dipipanone;
- (33) Ethylmethylthiambutene;
- (34) 2-(2-(4-ethoxybenzyl)-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine (Other names: etodesnitazene; etazene);
- (35) Etonitazene;
- (36) Etoxidine;
- (37) Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate);
- \*(38) Flunitazene (*N,N*-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine);
- (39) 4-Fluoroisobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide) (Other name: *p*-fluoroisobutyryl fentanyl);
- (40) 2'-Fluoro *o*-fluorofentanyl (*N*-(1-(2-fluorophenethyl)piperidin-4-yl)-*N*-(2-fluorophenyl)propionamide) (Other name: 2'-fluoro 2-fluorofentanyl);
- (41) Furanyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylfuran-2-carboxamide);
- (42) 3-Furanyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylfuran-3-carboxamide);
- (43) Furethidine;
- (44) Hydroxypethidine;
- (45) Isobutyryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylisobutyramide);
- (46) Isotonitazene (*N,N*-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine);
- (47) Isovaleryl fentanyl (3-methyl-*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide);
- (48) Ketobemidone;
- (49) Levophenacymorphan;
- (50) *m*-Fluorofentanyl (*N*-(3-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide);
- (51) *m*-Fluoroisobutyryl fentanyl (*N*-(3-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide);
- (52) Meprodine;
- (53) Methadol;
- (54) Methoxyacetyl fentanyl (2-methoxy-*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacetamide);
- (55) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one);
- (56) 4'-Methyl acetyl fentanyl (*N*-(1-(4-methylphenethyl)piperidin-4-yl)-*N*-phenylacetamide);

- (57) 3-Methylfentanyl (*N*-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-*N*-phenylpropanamide);
- (58) 3-Methylthiofentanyl (*N*-[3-methyl-1-(2-thienyl)ethyl-4-piperidiny]-*N*-phenylpropanamide);
- \*(59) Metodesnitazene (*N,N*-diethyl-2-(2-(4-methoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine);
- (60) Metonitazene (*N,N*-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine);
- (61) Moramide;
- (62) Morpheridine;
- (63) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- (64) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
- (65) Noracymethadol;
- (66) Norlevorphanol;
- (67) Normethadone;
- (68) Norpipanone;
- (69) 2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1*H*-benzimidazole (other names: *N*-pyrrolidino etonitazene; etonitazepyne);
- (70) Ocfentanil (*N*-(2-fluorophenyl)-2-methoxy-*N*-(1-phenethylpiperidin-4-yl)acetamide);
- (71) *o*-Fluoroacryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)acrylamide);
- (72) *o*-Fluorobutyryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide) (Other name: 2-fluorobutyryl fentanyl);
- (73) *o*-Fluorofentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 2-fluorofentanyl);
- (74) *o*-Fluorofuranyl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
- (75) *o*-Fluoroisobutyryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide);
- (76) *o*-Methyl acetylfentanyl (*N*-(2-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl acetylfentanyl);
- (77) *o*-Methyl methoxyacetyl fentanyl (2-methoxy-*N*-(2-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl methoxyacetyl fentanyl);
- (78) *p*-Chloroisobutyryl fentanyl (*N*-(4-chlorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide);
- (79) *p*-Fluorobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide);
- (80) *p*-Fluorofentanyl (*N*-(4-fluorophenyl)-*N*-[1-(2-phenethyl)-4 piperidiny] propanamide);
- (81) *p*-Fluoro furanyl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);

- (82) *p*-Methoxybutyryl fentanyl (*N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide);
- (83) *p*-Methoxyfuranyl fentanyl (*N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
- (84) *p*-Methylcyclopropyl fentanyl (*N*-(4-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
- (85) *p*-Methylfentanyl (*N*-(4-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 4-methylfentanyl);
- (86) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- (87) Phenadoxone;
- (88) Phenampromide;
- (89) Phencyclidine;
- (90) Phenomorphan;
- (91) Phenoperidine;
- (92) Phenyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbenzamide) (Other name: benzoyl fentanyl);
- (93) Piritramide;
- (94) Proheptazine;
- (95) Properidine;
- (96) Propiram;
- (97) *N,N*-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine (other name: protonitazene);
- (98) Tetrahydrofuranyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenyltetrahydrofuran-2-carboxamide);
- (99) Thiofentanyl (*N*-phenyl-*N*-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
- (100) Thiofuranyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylthiophene-2-carboxamide) (Other names: 2-thiofuranyl fentanyl; thiophene fentanyl);
- (101) Tilidine;
- (102) Trimeperidine;
- (103) U-47700 (3,4-dichloro-*N*-[2-(dimethylamino)cyclohexyl]-*N*-methylbenzamide);
- (104) Valeryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylpentanamide); and,
- (105) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol).

## **-Schedule I Stimulants**

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including the substance's salts, isomers, and salts of isomers if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) Amineptine 7-((10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)amino)heptanoic acid;
- (2) Aminorex (Other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5-phenyl-2-oxazolamine);
- (3) *N*-Benzylpiperazine (Other names: BZP; 1-benzylpiperazine), its optical isomers, salts and salts of isomers;
- (4) Cathinone (Other names: 2-amino-1-phenyl-1-propanone;  $\alpha$ -aminopropiophenone; 2-aminopropiophenone; norephedrone);
- (5) 4,4'-Dimethylaminorex (4,4'-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);
- \* (6) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate);
- (7) Fenethylamine;
- (8) Methcathinone (Other names: 2-(methylamino)-propionophenone;  $\alpha$ -(methylamino)propionophenone; 2-(methylamino)-1-phenylpropan-1-one;  $\alpha$ -*N*-methylaminopropionophenone; monomethylpropion; ephedrone; *N*-methylcathinone; methylcathinone; AL-464; AL-422; AL-463; UR1432);
- (9) Mesocarb *N*-phenyl-*N'*-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate);
- (10) Methiopropamine *N*-methyl-1-(thiophen-2-yl)propan-2-amine;
- (11) 4-Methylaminorex (Other names: U4Euh; McN-422);
- (12) *N*-Ethylamphetamine; and
- (13) *N,N*-Dimethylamphetamine (Other names: *N,N*- $\alpha$ -trimethylbenzene-ethaneamine; *N,N*- $\alpha$ -trimethylphenethylamine).

**-Schedule I Temporarily Listed Substances Subject to Emergency Scheduling by the U.S. Drug Enforcement Administration**

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances or that contains any of the substance's isomers, esters, ethers, salts and salts of isomers, esters, and ethers if the existence of the salts, esters, ethers isomers, and salts of isomers, esters, ethers is possible within the specific chemical designation:

- (1) Fentanyl-related substances.

(1-1) Fentanyl-related substance means any substance not otherwise listed under another Administration Controlled Substance Code Number, and for which no exemption or approval is in effect under Section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that is structurally related to fentanyl by one or more of the following modifications:

(1-1-1) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;

(1-1-2) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro groups;

(1-1-3) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;

(1-1-4) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; and/or

(1-1-5) Replacement of the *N*-propionyl group by another acyl group.

(1-2) This definition includes, but is not limited to, the following substances:

(1-2-1) *N*-(1-(2-Fluorophenethyl)piperidin-4-yl)-*N*-(2-fluorophenyl)propionamide (Other name: 2'-fluoro-*o*-fluorofentanyl);

(1-2-2) *N*-(2-Methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide (Other name: *o*-methyl acetylfentanyl);

(1-2-3) *N*-(1-Phenethylpiperidin-4-yl)-*N*,3-diphenylpropanamide (Other names:  $\beta'$ -phenyl fentanyl; hydrocinnamoyl fentanyl); and,

(1-2-4) *N*-(1-Phenethylpiperidin-4-yl)-*N*-phenylthiophene-2-carboxamide (Other name: thiofuranyl fentanyl).

(2) 4-(2-chlorophenyl)-2-ethyl-9-methyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (Other name: etizolam);

(3) 8-chloro-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (Other name: flualprazolam);

(4) 6-(2-chlorophenyl)-1-methyl-8-nitro-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (Other name: clonazolam);

(5) 8-bromo-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (Other names: 8-bromo-6-(2-fluorophenyl)-1-methyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine and flubromazolam);

(6) 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-benzo[*e*][1,4]diazepin-2-one (Other name: diclazepam);

(7) Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1*H*-indazole-3-carboxamido)butanoate (Other name: MDMB-4en-PINACA);

(8) Methyl 2-[[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (Other names: 4F-MDMB-BUTICA; 4F-MDMB-BICA);

(9) *N*-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1*H*-indazole-3-carboxamide (Other name: ADB-4en-PINACA);

(10) 5-Pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-*b*]indol-1-one (Other names: CUMYL-PEGACLONE; SGT-151);

- (11) Ethyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (Other names: 5F-EDMB-PICA; 5F-EDMB-2201);
- (12) Methyl 2-(1-(4-fluorobenzyl)-1*H*-indole-3-carboxamido)-3-methylbutanoate (Other name: MMB-FUBICA);
- \*(13) *N*-ethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine (Other name: *N*-desethyl isotonitazene); and
- \*(14) 2-(4-ethoxybenzyl)-5-nitro-1-(2-(piperidin-1-yl)ethyl)-1*H*-benzimidazole (Other names: *N*-piperidinyl etonitazene; etonitazepipne).

---

Jennifer Shuford, M.D., M.P.H.

---

Date

TRD-202500754  
 Cynthia Hernandez  
 General Counsel  
 Department of State Health Services  
 Filed: February 27, 2025



**Texas Department of Insurance**

Company Licensing

Application to do business in the state of Texas for Nevada General Insurance Company, a foreign fire and/or casualty company. The home office is in Carson City, Nevada.

Application for Bestow Life Insurance Company, a foreign life, accident and/or health company, to change its name to Lantern Insurance Company. The home office is in West Des Moines, Iowa.

Any objections must be filed with the Texas Department of Insurance, within twenty (20) calendar days from the date of the *Texas Register* publication, addressed to the attention of Andrew Guerrero, 1601 Congress Ave., Suite 6.900, Austin, Texas 78711.

TRD-202500801  
 Justin Beam  
 Chief Clerk  
 Texas Department of Insurance  
 Filed: March 5, 2025



**Texas Lottery Commission**

Notice of Public Comment Hearing

A public hearing to receive comments regarding proposed amendments to 16 TAC §§401.158 (Suspension or Revocation of License), 401.160 (Standard Penalty Chart), and 401.355 (Restricted Sales) will be held on Thursday, April 3, 2025, at 10:00 a.m., at 1801 Congress Ave., Austin, Texas 78701, George H. W. Bush Building, 4<sup>th</sup> Floor, Board Room 4.300. The purpose of the proposed amendments is to promote and ensure integrity, security, honesty, and fairness in the operation and administration of the Texas Lottery by prohibiting the use of lottery

ticket courier services that, by any remote means, such as telephone, Internet application, or mobile application, accept and fulfill, for a fee or compensation, orders to purchase lottery tickets on behalf of another person not present to effect an in-person sale (couriers). The Texas Lottery Commission intends to exercise this authority through administrative enforcement proceedings to revoke the lottery ticket sales agent license of a retailer that works in concert with a courier, whether under a common ownership arrangement or otherwise.

Persons requiring any accommodation for disability should notify Dorota Bienkowska at (512) 344-5392 or via email at dorota.bienkowska@lottery.state.tx.us at least 72 hours prior to the public hearing.

TRD-202500799  
 Bob Biard  
 General Counsel  
 Texas Lottery Commission  
 Filed: March 5, 2025



Scratch Ticket Game Number 2636 "\$1,000,000 RICHES"

1.0 Name and Style of Scratch Ticket Game.

A. The name of Scratch Ticket Game No. 2636 is "\$1,000,000 RICHES". The play style is "key number match".

1.1 Price of Scratch Ticket Game.

A. The price for Scratch Ticket Game No. 2636 shall be \$10.00 per Scratch Ticket.

1.2 Definitions in Scratch Ticket Game No. 2636.

A. Display Printing - That area of the Scratch Ticket outside of the area where the overprint and Play Symbols appear.

B. Latex Overprint - The removable scratch-off covering over the Play Symbols on the front of the Scratch Ticket.

C. Play Symbol- The printed data under the latex on the front of the Scratch Ticket that is used to determine eligibility for a prize. Each Play Symbol is printed in Symbol font in black ink in positive except for dual-image games. The possible black Play Symbols are: 01, 03,